Noun
DLBCL (plural DLBCLs)
(abbreviation) diffuse large B-cell lymphoma
To date, only 2 CAR-T therapies - Gilead's () Yescarta and Novartis' Kymriah - have been approved, both for relapsed/refractory Diffuse Large B-Cell Lymphoma ("DLBCL"). Source: Internet
Two of the most common types, diffuse large B-cell lymphoma (DLBCL), are very different in how, when and where they develop and how they are managed. Source: Internet